Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Department of Rheumatology, School of Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Department of Rheumatology, School of Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Int J Rheum Dis. 2019 Nov;22(11):1978-1984. doi: 10.1111/1756-185X.13662. Epub 2019 Jul 23.
Opportunistic infections (OIs) adversely affect outcomes in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). This study aimed to identify the incidence proportion of risk factors for OIs in patients with AAV who were on remission-induction therapy, using a Japanese health insurance database.
This retrospective longitudinal population-based study was conducted using claims data provided by Medical Data Vision Co., Ltd. We defined individuals as AAV cases receiving remission-induction therapy if they met all of the following criteria: (a) having OIs with at least 1 specified International Statistical Classification of Diseases and Related Health Problems, 10th Revision code (M300, M301, M313, or M318); (b) receiving at least 1 prescription of oral corticosteroids (CS) with prednisolone (PSL)-equivalent dosage ≥30 mg/d, CS pulse therapy, immunosuppressive agents or rituximab during hospitalization between April 2008 and April 2017; and (c) at least 7 days of hospitalization while on the above-mentioned therapies. We calculated incidence and proportion of OIs during the year following remission-induction therapy and the adjusted odds ratio (OR) using a logistic regression model.
We included 2299 patients with AAV in this study. OIs occurred in 460 patients (20.0%), with the most frequently occurring OI being cytomegalovirus infection (n = 122, 6.5%). After adjusting for covariates, age by decade (OR 1.24, 95% CI: 1.12-1.36), daily PSL dose per 10 mg (OR 1.16, 95% CI: 1.08-1.25), and CS pulse therapy (OR 1.29, 95% CI: 1.04-1.60) were found to be significantly associated with occurrence of OIs.
Older age and corticosteroid use were found to be significant risk factors for OIs in patients with AAV on remission-induction therapy, using a health insurance database.
机会性感染(OI)会对接受抗中性粒细胞胞浆抗体相关性血管炎(AAV)缓解诱导治疗的患者的结局产生不良影响。本研究旨在使用日本健康保险数据库,确定处于缓解诱导治疗中的 AAV 患者发生 OI 的风险因素的比例。
这是一项使用医疗数据视觉有限公司提供的理赔数据进行的回顾性纵向基于人群的研究。我们将符合以下所有标准的个体定义为接受缓解诱导治疗的 AAV 病例:(a)患有至少 1 种特定的国际疾病分类第十版(M300、M301、M313 或 M318)规定的 OI;(b)在 2008 年 4 月至 2017 年 4 月期间住院期间至少接受 1 种口服皮质类固醇(CS)的处方,泼尼松龙(PSL)等效剂量≥30mg/d、CS 脉冲治疗、免疫抑制剂或利妥昔单抗;(c)在接受上述治疗期间至少住院 7 天。我们计算了缓解诱导治疗后 1 年内 OI 的发生率和比例,并使用逻辑回归模型计算了调整后的比值比(OR)。
本研究共纳入了 2299 例 AAV 患者。460 例患者(20.0%)发生了 OI,最常见的 OI 是巨细胞病毒感染(n=122,6.5%)。在调整了协变量后,年龄(每十年增加 1.24,95%置信区间:1.12-1.36)、每天 PSL 剂量每增加 10mg(OR 1.16,95%置信区间:1.08-1.25)和 CS 脉冲治疗(OR 1.29,95%置信区间:1.04-1.60)与 OI 的发生显著相关。
使用健康保险数据库,我们发现年龄较大和皮质类固醇的使用是接受缓解诱导治疗的 AAV 患者发生 OI 的显著风险因素。